3D QSAR studies on a series of potent and high selective inhibitors for three kinases of RTK family

Journal of Molecular Graphics and Modelling

Volumn 26, Issue 1, 2007, Pages 236-245

  Cao, Hongyu ^b   Zhang, Huabei ^a   Zheng, Xuefang ^b   Gao, Dabin ^b  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b DALIAN UNIVERSITY   (China)

Author keywords

cKit; CoMFA; CoMSIA; KDR; Selective inhibitor; Tie 2

Indexed keywords

DATA STRUCTURES; MATHEMATICAL MODELS; MOLECULAR STRUCTURE;

COMSIA MODELS; SYNERGISTIC EFFECT;

ENZYME INHIBITION;

ANGIOPOIETIN RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR;

ARTICLE; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPARATIVE MOLECULAR SIMILARITY INDICES ANALYSIS; IC 50; LIGAND BINDING; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

BINDING SITES; COMPUTER GRAPHICS; COMPUTER SIMULATION; DRUG DESIGN; ELECTROSTATICS; LIGANDS; MODELS, MOLECULAR; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, TIE-2; THERMODYNAMICS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 34250797428     PISSN: 10933263     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmgm.2006.12.001     Document Type: Article

References (30)

1. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 (2000) 249-257
2. Folkman J. Clinical applications of research on angiogenesis. N. Engl. J. Med. 333 (1995) 1757-1763
3. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1 (1995) 27-31
4. Zetter B.R. Angiogenesis and tumor metastasis. Annu. Rev. Med. 49 (1998) 407-424
5. Kuethe J.T., Wong A., Qu C.X., Smitrovich J., Davies I.W., and Hughes D.L. Synthesis of 5-substituted-1H-indol-2-yl-1H-quinolin-2-ones: a novel class of KDR kinase inhibitors. J. Org. Chem. 70 (2005) 2555-2567
6. Thomas K.A. Vascular endothelial growth factor, a potent and selective angiogenic agent. J. Biol. Chem. 271 (1996) 603-606
7. Terman B.I., Dougher-Vermazen M., Carrion M.E., Dimitrov D., Armellino D.C., Gospodarowicz D., and Bohlen P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun. 187 3 (1992) 1579-1586
8. De Vries C., Escobedo J.A., Ueno H., Houck K., Ferrara N., and Williams L.T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255 (1992) 989-991
9. Yancopoulos G.D., Davis S., Gale N.W., Rudge J.S., Wiegand S.J., and Holash J. Vascular-specific growth factors and blood vessel formation. Nature 407 (2000) 242-248
10. Bilodeau M.T., Fraley M.E., and Hartman G.D. Kinase insert domain-containing receptor kinase inhibitors as anti-angiogenic agents. Expert Opin. Investig. Drugs 11 (2002) 737-745
11. Shibuya M., and Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp. Cell Res. 312 (2006) 549-560
12. Dikov M.M., Ohm J.E., Ray N., Tchekneva E.E., Burlison J., Moghanaki D., Nadaf S., and Carbone D.P. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J. Immunol. 174 (2005) 215-222
13. Mol C.D., Dougan D.R., Schneider T.R., Skene R.J., Kraus M.L., Scheibe D.N., Snell G.P., Zou H., Sang B.C., and Wilson K.P. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J. Biol. Chem. 279 (2004) 31655-31663
14. Niu X.L., Peters K.G., and Kontos C.D. Deletion of the carboxyl terminus of Tie2 enhances kinase activity, signaling, and function. Evidence for an autoinhibitory mechanism. J. Biol. Chem. 277 (2002) 31768-31773
15. Lin P.N., Buxton J.A., Acheson A., Radziejewski C., Maisonpierre P.C., and Peters K.G. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 8829-8834
16. Siemeister G., Schirner M., Weindel K., Reusch P., Menrad A., Marme D., and Martiny-Baron G. Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway. Cancer Res. 59 (1999) 3185-3191
17. Lin P.N., Polverini P., Dewhirst M., Shan S.Q., Rao P.S., and Peters K. Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. J. Clin. Invest. 100 (1997) 2072-2078
18. Ferrara N., and Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev. 18 (1997) 4-25
19. Borgstroem P., Hillan K.J., Sriramarao P., and Ferrara N. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital video microscopy. Cancer Res. 56 (1996) 4032-4039
20. Adamis A.P., Shima D.T., Tolentino M.J., Gragoudas E.S., Ferrara N., Folkman J., D'Amore P.A., and Miller J.W. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch. Ophthalmol. 114 (1996) 66-71
21. Koblizek T.I., Weiss C., Yancopoulos G.D., Deutsch U., and Risau W. Angiopoietin-1 induces sprouting angiogenesis in vitro. Curr. Biol. 8 (1998) 529-532
22. Witzenbichler B., Maisonpierre P.C., Jones P., Yancopoulos G.D., and Isner J.M. Chemotactic properties of angiopoietin-1 and -2, ligands for the endothelial-specific receptor tyrosine kinase Tie2. J. Biol. Chem. 273 (1998) 18514-18521
23. Shewchuk L.M., Hassell A.M., Ellis B., Holmes W.D., Davis R., Horne E.L., Kadwell S.H., McKee D.D., and Moore J.T. Structure of the Tie2 RTK doma self-inhibition by the nucleotide binding loop activation loop C-terminal tail. Structure 8 (2000) 1105-1113
24. Cramer III R.D., Patterson D.E., and Bunce J.D. Comparative molecular field analysis (CoMFA) 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 110 (1988) 5959-5967
25. Klebe G., Abraham U., and Mietzner T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J. Med. Chem. 37 (1994) 4130-4146
26. SYBYL 7.0 Manual, Tripos Inc., St. Louis, USA, 2004.
27. Baskin I.I., Tikhonova I.G., Palyulin V.A., and Zefirov N.S. Selectivity fields: comparative molecular field analysis (CoMFA) of the glycine/NMDA and AMPA receptors. J. Med. Chem. 46 (2003) 4063-4069
28. Dai Y.J., Guo Y., Frey R.R., Ji Z.Q., Curtin M.L., Ahmed A.A., Albert D.H., Arnold L., Arries S.S., Barlozzari T., Bauch J.L., Bouska J.J., Bousquet P.F., Cunha G.A., Glaser K.B., Guo J., Li J.L., Marcotte P.A., Marsh K.C., Moskey M.D., Pease L.J., Stewart K.D., Stoll V.S., Tapang P., Wishart N., Davidsen S.K., and Michaelides M.R. Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. J. Med. Chem. 48 (2005) 6066-6083
29. Miyazaki Y., Matsunaga S., Tang J., Maeda Y., Nakano M., Philippe R.J., Shibahara M., Liu W., Sato H., Wang L.P., and Nolte R.T. Novel 4-aminofuro[2,3-d]pyrimidines as Tie-2 and VEGFR2 dual inhibitors. Bioorg. Med. Chem. Lett. 15 (2005) 2203-2207
30. Thibaut U., Folkers G., Klebe G., Kubinyi H., Merz A., and Rognan D. Recommendations to CoMFA studies and 3D QSAR publications. In: Kubinyi H. (Ed). 3D QSAR in Drug Design. Theory, Methods and Applications (1993), ESCOM, Leiden, The Netherlands 711-716